Transplantation of a kidney with a heterozygous mutation in the SLC22A12 (URAT1) gene causing renal hypouricemia: a case report.
Adult
Chimerism
Female
Heterozygote
High-Throughput Nucleotide Sequencing
Humans
Kidney Transplantation
Kidney Tubules
/ metabolism
Living Donors
Male
Mutation, Missense
Organic Anion Transporters
/ genetics
Organic Cation Transport Proteins
/ genetics
Renal Elimination
/ genetics
Renal Tubular Transport, Inborn Errors
/ genetics
Siblings
Uric Acid
/ metabolism
Urinary Calculi
/ genetics
Chimerism
Fluorescence in situ hybridization
Renal allografts
Renal hypouricemia
SLC22A12
Journal
BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793
Informations de publication
Date de publication:
16 07 2020
16 07 2020
Historique:
received:
12
05
2020
accepted:
08
07
2020
entrez:
18
7
2020
pubmed:
18
7
2020
medline:
14
10
2021
Statut:
epublish
Résumé
Renal hypouricemia (RHUC) is a genetic disorder caused by mutations in the SLC22A12 gene, which encodes the major uric acid (UA) transporter, URAT1. The clinical course of related, living donor-derived RHUC in patients undergoing kidney transplantation is poorly understood. Here, we report a case of kidney transplantation from a living relative who had an SLC22A12 mutation. After the transplantation, the recipient's fractional excretion of UA (FEUA) decreased, and chimeric tubular epithelium was observed. A 40-year-old man underwent kidney transplantation. His sister was the kidney donor. Three weeks after the transplantation, he had low serum-UA, 148.7 μmol/L, and elevated FEUA, 20.8% (normal: < 10%). The patient's sister had low serum-UA (101.1 μmol/L) and high FEUA (15.8%) before transplant. Suspecting RHUC, we performed next-generation sequencing on a gene panel containing RHUC-associated genes. A heterozygous missense mutation in the SLC22A12 gene was detected in the donor, but not in the recipient. The recipient's serum-UA level increased from 148.7 μmol/L to 231.9 μmol/L 3 months after transplantation and was 226.0 μmol/L 1 year after transplantation. His FEUA decreased from 20.8 to 11.7% 3 months after transplantation and was 12.4% 1 year after transplantation. Fluorescence in situ hybridization of allograft biopsies performed 3 months and 1 year after transplantation showed the presence of Y chromosomes in the tubular epithelial cells, suggesting the recipient's elevated serum-UA levels were owing to a chimeric tubular epithelium. We reported on a kidney transplant recipient that developed RHUC owing to his donor possessing a heterozygous mutation in the SLC22A12 (URAT1) gene. Despite this mutation, the clinical course was not problematic. Thus, the presence of donor-recipient chimerism in the tubular epithelium might positively affect the clinical course, at least in the short-term.
Sections du résumé
BACKGROUND
Renal hypouricemia (RHUC) is a genetic disorder caused by mutations in the SLC22A12 gene, which encodes the major uric acid (UA) transporter, URAT1. The clinical course of related, living donor-derived RHUC in patients undergoing kidney transplantation is poorly understood. Here, we report a case of kidney transplantation from a living relative who had an SLC22A12 mutation. After the transplantation, the recipient's fractional excretion of UA (FEUA) decreased, and chimeric tubular epithelium was observed.
CASE PRESENTATION
A 40-year-old man underwent kidney transplantation. His sister was the kidney donor. Three weeks after the transplantation, he had low serum-UA, 148.7 μmol/L, and elevated FEUA, 20.8% (normal: < 10%). The patient's sister had low serum-UA (101.1 μmol/L) and high FEUA (15.8%) before transplant. Suspecting RHUC, we performed next-generation sequencing on a gene panel containing RHUC-associated genes. A heterozygous missense mutation in the SLC22A12 gene was detected in the donor, but not in the recipient. The recipient's serum-UA level increased from 148.7 μmol/L to 231.9 μmol/L 3 months after transplantation and was 226.0 μmol/L 1 year after transplantation. His FEUA decreased from 20.8 to 11.7% 3 months after transplantation and was 12.4% 1 year after transplantation. Fluorescence in situ hybridization of allograft biopsies performed 3 months and 1 year after transplantation showed the presence of Y chromosomes in the tubular epithelial cells, suggesting the recipient's elevated serum-UA levels were owing to a chimeric tubular epithelium.
CONCLUSIONS
We reported on a kidney transplant recipient that developed RHUC owing to his donor possessing a heterozygous mutation in the SLC22A12 (URAT1) gene. Despite this mutation, the clinical course was not problematic. Thus, the presence of donor-recipient chimerism in the tubular epithelium might positively affect the clinical course, at least in the short-term.
Identifiants
pubmed: 32677916
doi: 10.1186/s12882-020-01940-4
pii: 10.1186/s12882-020-01940-4
pmc: PMC7364597
doi:
Substances chimiques
Organic Anion Transporters
0
Organic Cation Transport Proteins
0
SLC22A12 protein, human
0
Uric Acid
268B43MJ25
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
282Références
Clin Genet. 2008 Sep;74(3):243-51
pubmed: 18492088
Nephrol Dial Transplant. 2011 Jul;26(7):2175-81
pubmed: 21148271
Klin Wochenschr. 1989 Mar 1;67(5):308-12
pubmed: 2709741
Nature. 2002 May 23;417(6887):447-52
pubmed: 12024214
Am J Med. 1972 Sep;53(3):361-7
pubmed: 5054729
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
J Am Soc Nephrol. 2004 Jan;15(1):164-73
pubmed: 14694169
Clin Nephrol. 2012 Feb;77(2):161-3
pubmed: 22257548
PLoS One. 2011;6(12):e28641
pubmed: 22194875
Circ J. 2015;79(5):1125-32
pubmed: 25739858
Nephrol Dial Transplant. 2004 Jun;19(6):1447-53
pubmed: 15150354
Pediatr Int. 2007 Apr;49(2):235-7
pubmed: 17445045
Am J Kidney Dis. 1995 Jun;25(6):937-46
pubmed: 7771493
BMC Med Genet. 2014 Jan 07;15:3
pubmed: 24397858
J Am Soc Nephrol. 2004 Feb;15(2):261-8
pubmed: 14747372
Nephron. 1993;65(4):578-82
pubmed: 8302413
Nephrol Dial Transplant. 2006 Jul;21(7):2041
pubmed: 16449280
BMC Med Genet. 2018 Aug 10;19(1):142
pubmed: 30097038
Contrib Nephrol. 1992;100:1-14
pubmed: 1458896
Nephrology (Carlton). 2016 Jul;21 Suppl 1:67-71
pubmed: 26971588
Am J Nephrol. 2013;38(4):316-20
pubmed: 24107611
Pathol Int. 2012 Apr;62(4):254-63
pubmed: 22449229
Clin Exp Nephrol. 2017 Feb;21(1):63-75
pubmed: 26920127
Kidney Int. 2004 Sep;66(3):935-44
pubmed: 15327384